全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
Core Evidence  2013 

An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies

DOI: http://dx.doi.org/10.2147/CE.S42568

Keywords: obatoclax, leukemia, lymphoma, myelofibrosis, BCL-2, BH3 mimetic

Full-Text   Cite this paper   Add to My Lib

Abstract:

n evidence-based review of obatoclax mesylate in the treatment of hematological malignancies Review (136) Total Article Views Authors: Goard CA, Schimmer AD Published Date March 2013 Volume 2013:8 Pages 15 - 26 DOI: http://dx.doi.org/10.2147/CE.S42568 Received: 09 January 2013 Accepted: 05 February 2013 Published: 14 March 2013 Carolyn A Goard, Aaron D Schimmer Princess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada Abstract: Obatoclax mesylate is an intravenously-administered drug under investigation in Phase I and II clinical trials as a novel anticancer therapeutic for hematological malignancies and solid tumors. Obatoclax was developed as a pan-inhibitor of antiapoptotic members of the B cell chronic lymphocytic leukemia/lymphoma 2 (BCL-2) family of proteins, which control the intrinsic or mitochondrial pathway of apoptosis. Resistance to apoptosis through dysregulation of BCL-2 family members is commonly observed in hematological malignancies, and can be linked to therapeutic resistance and poor clinical outcomes. By inhibiting pro-survival BCL-2 family proteins, including MCL-1, obatoclax is proposed to (1) trigger cell death as a single agent, and (2) potentiate the anticancer effects of other therapeutics. Preclinical investigations have supported these proposals and have provided evidence suggestive of a promising therapeutic index for this drug. Phase I trials of obatoclax mesylate in leukemia and lymphoma have defined well-tolerated regimens and have identified transient neurotoxicity as the most common adverse effect of this drug. In these studies, a limited number of objective responses were observed, along with hematological improvement in a larger proportion of treated patients. Published Phase II evaluations in lymphoma and myelofibrosis, however, have not reported robust single-agent activity. Emerging evidence from ongoing preclinical and clinical investigations suggests that the full potential of obatoclax mesylate as a novel anticancer agent may be realized (1) in rational combination treatments, and (2) when guided by molecular predictors of therapeutic response. By understanding the molecular underpinnings of obatoclax response, along with optimal therapeutic regimens and indications, the potential of obatoclax mesylate for the treatment of hematological malignancies may be further clarified.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133